Next-Generation Drug Delivery Platform

PRECISION

LOCALIZED

THERAPY

For many cancer therapies, often less than 1% of a systemically administered drug reaches the tumor site. KINETIX uses machine learning to optimize scaffold architecture and deliver therapy precisely where disease lives.

The Crisis in Drug Delivery

A broken system.
Measured in lives and dollars.

0K+
Drug-related deaths / yr
$0.0B
Annual economic burden
<0.0%
Of cancer drugs reaching the tumor site
01

Low Bioavailability

Most systemically administered therapies are metabolized or diluted before reaching the target tissue, forcing higher doses that amplify side effects and increase patient risk.

02

Systemic Toxicity

Drugs flood healthy tissue alongside disease sites, forcing clinicians to choose between therapeutic efficacy and patient safety, a compromise KINETIX eliminates.

03

Uncontrolled Release

Conventional formulations offer no programmable control over release timing or concentration, an irreducible structural constraint on precision medicine.

The Platform

Structure-driven control.
Precision delivery at the site of disease.

01

Localized Delivery

Millimeter-scale scaffolds implanted directly at the site of disease, maximizing local drug concentration while eliminating the systemic exposure that causes toxicity and side effects.

Implantable Scaffold SystemsSite-Specific TherapyZero Systemic Exposure
02

Programmable Release

Drug release profiles engineered into the physical architecture of each scaffold. Therapy timing, duration, and concentration governed through structure, not chemistry alone.

Controlled Release KineticsTemporal PrecisionDose Consistency
03

Patient-Specific Design

Machine learning simultaneously optimizes over 14 internal geometry properties to each patient's therapeutic profile, and generates a matched hydrogel loading mold alongside the scaffold, enabling personalized drug delivery at clinical scale without manual engineering overhead.

ML-Optimized ArchitectureAI-Generated BlueprintsPersonalized Therapy
Core Innovation

Biomaterials as precision instruments.

01

Beyond Chemistry

Traditional drug delivery relies on chemical formulation to modulate release. KINETIX controls release through geometry, through physical architecture that determines how and when therapeutics diffuse into surrounding tissue.

Architecture-Controlled ReleaseGeometry-Driven Kinetics
02

Structure Equals Function

Over 14 internal geometry properties, including porosity, channel architecture, and surface topology, are resolved at millimeter-scale precision and directly determine release performance. The scaffold is not a container. The scaffold is the delivery mechanism.

Functional MetamaterialsStructural Drug Control
03

Design-Driven Precision

Scaffold architectures generated and refined by machine learning to hit precise therapeutic targets. Performance is not approximated through trial and error. It is designed, validated, and delivered with predictive accuracy.

Computational DesignValidated Predictive Control
Passive drug carrier
Actively engineered therapeutic instrument
Validation

Real scaffolds. Real biology.
Validated performance.

0%+
Correlation: Predicted vs. Experimental
0+
Physical Scaffolds Experimentally Tested
0%
Results Within Agreement Bounds
<0%
Error Rate Across All Validation Experiments
0+
Scaffold Geometry Properties To Optimize

What this means in practice.

01

Fewer treatment cycles required to achieve therapeutic targets

02

Significantly reduced systemic toxicity burden on patients

03

More consistent and reproducible treatment outcomes

04

Lower effective dosage and lower cost of therapy

Applications

One platform.
Multiple therapeutic frontiers.

Oncology

Implantable scaffolds deliver chemotherapy directly at the tumor site. Therapeutic concentrations maximized at the target while systemic drug load, and its associated toxicity, is dramatically curtailed.

Localized chemotherapyTumor microenvironmentReduced systemic toxicity

Neuroregeneration

Neuroprotective and regenerative agents released precisely at sites of stroke injury or peripheral nerve damage, providing a sustained therapeutic environment that systemic delivery cannot replicate.

Post-stroke therapyNerve regenerationSustained neuroprotection

Cardiac Repair

Following myocardial infarction, scaffolds release growth factors on a controlled timeline, supporting tissue recovery and reducing the chronic remodeling that leads to heart failure.

Post-MI therapyGrowth factor releaseCardiac remodeling

Orthopedic Healing

Bone-integrated scaffolds deliver antibiotics, growth factors, or regenerative agents precisely at fracture or implant sites, reducing infection risk while accelerating recovery.

Bone repairOsseointegrationAnti-infective delivery

Wound Healing

Programmable release of growth factors and bioactive compounds enables clinicians to tune therapeutic timing and concentration to individual patient healing profiles.

Chronic wound managementGrowth factor deliveryHealing acceleration

Tissue Engineering

Scaffolds engineered to replicate the structural complexity of native extracellular matrix enable cell-driven tissue repair, extending KINETIX into the full scope of regenerative medicine.

ECM mimicryCell scaffoldingRegenerative medicine

Working on a different indication? Let's discuss your clinical application.

Oncology CentersPharma R&DMedical Device FirmsHealth SystemsGlobal HealthVenture Capital
Platform in Action

See KINETIX generate a precision scaffold in real time.

Clinical goals in. Machine learning optimizes over 14 geometry properties. Validated scaffold and matched hydrogel loading mold out.

KINETIX Platform Demo

Ready to see it for your indication?

Schedule a briefing tailored to your therapeutic application.

Schedule a Live Demo
Economics of Precision

Breakthrough efficacy.
Accessible economics.

01

Ultra-Low Material Cost

$0.20 – $0.25 per scaffold. A precision drug delivery system at the cost of a pill.

02

<$8 Total Production

End-to-end fabrication of millimeter-scale scaffolds with high-precision 3D printing, covering materials, printing, and processing, under $8 per scaffold.

03

Scalable Manufacturing

3D printing compatibility means production scales with demand. Clinical volume is an operational challenge, not a technical one.

04

Global Clinical Access

Cost efficiency makes precision localized delivery viable beyond elite academic medical centers, across health systems worldwide.

Built forOncology CentersPharma R&DMedical Device FirmsHealth SystemsGlobal HealthVenture Capital
Explore Investment & Partnership
Get in Touch

Start a conversation.
Advance the science.

Clinical partnership, research collaboration, or investment: we want to hear from you.

Emailcontact@kinetix-dds.com
LocationPhoenix, AZ, USA

Prefer a direct conversation?

Submit the form and indicate your interest. We will follow up within 1-2 business days to arrange a call with the right member of our team.

We respond within 1–2 business days. Your information is never shared.